Quinnova begins marketing Neosalus

Quinnova Pharmaceuticals, a USA-based specialty dermatological pharmaceutical company focused on the development and commercial sale of  prescription drug products based on dermal drug delivery platforms, has  launched Neosalus, a non-steroidal anti-inflammatory prescription  topical foam product for the treatment of various types of dermatoses  including atopic dermatitis and hand eczema.

Unlike some creams and lotions that have a tendency to leave the skin  feeling greasy after application, the firm says Neosalus, a water-lipid  based foam, absorbs quickly, spreads easily and is non-greasy.

Senior vice presidentChristopher Hensby said: "Neosalus helps to restore  a dysfunctional skin barrier by replenishing the lost lipids, thereby  decreasing trans-epidermal water loss. Furthermore, Neosalus functions  as a protectant to reduce the penetration of irritants from further  exacerbating the itch and scratch cycle. Finally, Neosalus has  anti-inflammatory ability that helps to reduce the frequency and  severity of flare-ups, thus making it a steroid sparing and  complementary treatment to other concomitant treatments."